Science/Updates

VANCOUVER, British Columbia, March 20, 2026 — Reverb Therapeutics today announced the closing of a US$12 million top-up financing led by Amplitude Ventures, with participation from KdT Ventures, the Myeloma Investment Fund, Seido Capital, and InBC Investment Corp. Proceeds will be used to fund IND-enabling studies for AMP01, Reverb’s lead program.

AMP01 is a next-generation anti-PD-1 candidate that leverages Reverb’s proprietary Amplify•R™ technology to augment PD-1 blockade by stimulating endogenous IL-15 signaling in a safe and controlled way. Reverb is also advancing additional programs built on the Amplify•R platform to address significant unmet medical needs in cancer and autoimmune disease.

“Closing this financing is an important milestone for Reverb as we move AMP01 through IND-enabling studies and toward first-in-human evaluation,” said David de Graaf, Ph.D., Chief Executive Officer of Reverb Therapeutics. “With Amplify•R, we are working to deliver a next-generation approach to PD-1 blockade—one designed to selectively engage endogenous IL-15 biology in a PD-1–dependent manner. We’re grateful for the strong support from this investor group as we advance AMP01 and build a robust pipeline aimed at providing meaningful impact for patients across oncology and autoimmune disease.”

Bharat Srinisava, Ph.D., Reverb Board Member and Principal at Amplitude Ventures, said: “Reverb is pursuing a compelling, mechanistically differentiated strategy in immunotherapy, and we are excited to lead this financing to help accelerate AMP01 toward the clinic. The team has developed a thoughtful approach to enhancing PD-1 blockade through PD-1–dependent stimulation of endogenous IL-15 signaling. First-in-class AMP01 has the potential to translate into meaningful benefit for patients with life-altering disease. We look forward to supporting Reverb as it executes IND-enabling work for AMP01 and advances additional Amplify•R-enabled programs.”

###

About Reverb Therapeutics

Reverb Therapeutics creates new medicines using its proprietary Amplify•R™ antibody platform to intelligently control and direct the body’s own immune signals in treating cancer and auto-immune diseases. Our lead program, AMP01, is a first-in-class drug candidate that augments the proven benefits of PD-1 inhibition by selectively amplifying immune signals to intensify the anti-tumor response in a safe and controlled manner. Using proven biology and elegant rewiring of the immune system, we generate highly differentiated therapeutics, bringing new hope to patients for whom existing treatments have fallen short. Clinical trials are expected to start in early 2028.

Media contact:
Jeffrey Krasner, Liberty Square Group
krasner@libertysquaregroup.com
+1 617-840-9806